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        Introduction 
  The transition of immature Schwann cells to myelinating cells 
depends on promyelin gene regulatory proteins, including at 
least Krox-20, Nab1 and 2, Oct-6, Brn2, NF    B, and Sox-10 
(  Topilko et al., 1994  ;   Bermingham et al., 1996  ;   Jaegle et al., 2003  ; 
  Nickols et al., 2003  ;   Le et al., 2005a  ;   Ghislain and Charnay, 2006  ). 
Myelinating cells readily lose their myelin and can dedifferentiate 
to a phenotype that resembles the immature state, and this tran-
sition, like myelination, involves a complex and orderly cellular 
transformation (  Jessen and Mirsky, 2005  ). It is an important 
possibility that this reverse transition also requires distinct gene 
regulatory proteins that would function as negative regulators of 
the myelinated state and push myelinating cells back toward the 
immature phenotype. In this paper, we identify the basic leucine 
zipper protein c-Jun as a transcription factor that acts in this 
way in Schwann cells. 
  The ability of myelinating cells to dedifferentiate is seen 
when they are removed from axonal contact in injured nerves or 
in vitro and also in demyelinating neuropathies. Remarkably, 
dedifferentiated cells, even in adults, can remyelinate if they are 
allowed to associate with axons under appropriate conditions. 
Potentially, this choice between two alternative differentiation 
states is therefore open to Schwann cells throughout life. Stud-
ies of gene regulatory proteins that control the choice between 
two alternative fates have revealed the importance of cross-
antagonistic signaling systems where a major role in fate choice 
is played by the balance between two sets of transcription factors 
that both specify alternative fates and inhibit the expression or 
the activity of each other. Examples of this include the GATA-1/
c-Myb and GATA-1/PU.1 transcription factors in erythrocyte 
development and Scl(Tal1)/Olig2 in astrocyte development (  Cantor 
and Orkin, 2002  ;   Muroyama et al., 2005  ). 
  In Schwann cells, specifi  cation of myelin differentiation 
is dependent on the zinc fi  nger transcription factor Krox-20 
(Egr2). It is activated by the axonal signals that induce myelina-
tion. Krox-20 
   /     Schwann cells fail to myelinate, although they 
enter the earliest stage of myelination, the promyelin state. 
Enforced expression of Krox-20 in Schwann cells is suffi  cient 
to induce expression of myelin genes, remove cells from the cell 
cycle, and reduce susceptibility to apoptosis, all of which are 
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  This regulatory profi  le of the JNK  –  c-Jun pathway in vivo, i.e., 
down-regulation as immature cells myelinate and up-regulation 
in the proliferating cells of injured nerves, shows that c-Jun is 
present when Schwann cells proliferate, which is in agreement 
with a role for c-Jun in Schwann cell division (  Parkinson et al., 
2004  ). However, when proliferating Schwann cells are removed 
from perinatal nerves and made quiescent in vitro, they continue 
to express c-Jun, showing that c-Jun expression is not suffi  cient 
developmental changes that normally take place when myelin-
ation begins. Expression of Krox-20 therefore sets in train and/
or amplifi  es a set of changes associated with the adoption of a 
myelin fate (  Nagarajan et al., 2001  ;   Topilko and Meijer, 2001  ; 
  Parkinson et al., 2004  ). 
  The transcription factor c-Jun, which is studied here, is a 
key component of the AP-1 transcription factor complex and forms, 
with JunB and JunD, the Jun protein family (  Mechta-Grigoriou 
et al., 2001  ). Although the phosphorylation of c-Jun at NH  2 -
terminal Ser-63 and -73 residues by JNK is important for many 
of its functions, other actions of c-Jun are independent of c-Jun 
phosphorylation but dependent on the presence of the protein 
(  Raivich and Behrens, 2006  ). c-Jun is present in immature 
Schwann cells, but its expression is repressed by Krox-20 
(  Parkinson et al., 2004  ). Schwann cells therefore express low 
levels of c-Jun when they start myelinating. 
  In this paper, we report that c-Jun is an important regulator 
of Schwann cell differentiation because c-Jun acts as a potent 
suppressor of the myelin phenotype. This function is indepen-
dent of its role in proliferation and death. c-Jun blocks myelina-
tion in neuron  –  Schwann cell cocultures, opposes the function of 
Krox-20 and cAMP-related myelin signals, and drives the de-
differentiation of early myelinating cells back to the immature 
Schwann cell phenotype. This effect is seen in injured nerves 
both in vivo and in vitro, using mice with conditional inactiva-
tion of c-Jun in Schwann cells. Some of these effects of c-Jun 
are possibly channeled through Sox-2, a transcription factor that 
inhibits myelination (  Le et al., 2005b  ). We also show that c-Jun 
inhibits Krox-20 expression, suggesting that these proteins are 
components of a cross-inhibitory switch to control two alterna-
tive gene programs: while Krox-20 drives the myelination pro-
gram, c-Jun is a negative regulator of myelination that promotes 
the opposite program of dedifferentiation. 
  Results 
  c-Jun and phosphorylated c-Jun are down-
regulated during myelin differentiation and 
rapidly up-regulated as myelin breaks down 
in injured nerves 
  In early postnatal Schwann cells, c-Jun protein is down-
regulated as proliferation decreases and myelination begins. 
When it is reexpressed when nerves are injured, Schwann cells 
reenter the cell cycle and dedifferentiate (  De Felipe and Hunt, 
1994  ;   Stewart, 1995  ;   Shy et al., 1996  ). We confi  rmed this 
for c-Jun, phospho  –  c-Jun, JNK 1 and 2, and phospho-JNK1/2. 
Up-regulation of these components after nerve injury, particu-
larly of phospho-JNK1/2, was very rapid (  Fig. 1, A  –  C  ). When 
purifi  ed cultures of primary Schwann cells were exposed to 
dibutyryl cAMP (db-cAMP) to induce myelin differentiation, 
c-Jun and phospho  –  c-Jun were suppressed (  Fig. 1, D  –  H  ), 
which is in line with the down-regulation of c-Jun during my-
elination in vivo (  Monuki et al., 1989  ;   Stewart, 1995  ;   Shy et al., 
1996  ). Unlike in vivo, activation of myelin differentiation in 
these experiments did not involve cell cycle exit because the 
cells were quiescent before and after addition of db-cAMP (un-
published data). 
  Figure 1.       Components of the c-Jun pathway are regulated during 
  development, Wallerian degeneration, and in vitro differentiation.   A  –  D show 
Western blots. (A) Down-regulation of phospho  –  c-Jun and c-Jun proteins in 
sciatic nerve from embryonic day (E) 18 to adult. (B) Rapid up-regulation 
of JNK  –  c-Jun pathway components at 20 min (20  ’  )  –  12 h after nerve cut 
when compared with contralateral control (Con). (C) Strong increase in 
phospho  –  c-Jun at 1, 2, and 3 d after transection (Cut) compared with the 
contralateral control (Con). (D) Activation of cAMP-related pathways (1 mM 
db-cAMP for 24 h) decreases c-Jun and phospho  –  c-Jun and increases the 
myelin proteins Krox-20 and periaxin, whereas phospho-ERK1/2 levels 
are unchanged. (E  –  H) Double immunolabeling of controls (E and F) and 
cells treated with 1 mM db-cAMP for 3 d (G and H), with phospho  –  c-Jun 
and P  0   antibodies. Note that cAMP induces P  0   and suppresses phospho  – 
c-Jun levels in the P  0  -positive cells. Bar, 15   μ  m.     627   C  -J  UN   REPRESSES MYELINATION   •   Parkinson et al.
  By gene transfection, we enforced expression of two differ-
ent c-Jun molecules: Jun(Asp), in which all potential N-terminal 
phosphorylation sites have been mutated to aspartic acid, which 
mimics phosphorylated c-Jun; and Jun(Ala), in which all poten-
tial N-terminal phosphorylation sites are mutated to alanine 
and therefore cannot be phosphorylated by JNK (  Papavassiliou 
et al., 1995  ;   Watson et al., 1998  ). Using cotransfection, we showed 
that both Jun(Asp) and Jun(Ala) expression strongly (P  <   0.001) 
inhibit the induction of both periaxin and P  0   protein and mRNA 
by Krox-20 (  Fig. 3, A  –  G  ; and not depicted). Expression of 
for proliferation. Furthermore, when quiescent cells are induced 
by cAMP or enforced Krox-20 expression to adopt a myelin 
phenotype, c-Jun is down-regulated even when cell division is 
absent throughout the experiments (  Parkinson et al., 2004  ; pre-
vious paragraph). Therefore, both in vivo and in vitro, c-Jun ex-
pression is suppressed as Schwann cells myelinate. But only 
in vivo is this correlated with exit from the cell cycle. These obser-
vations led us to examine whether down-regulation of c-Jun is 
important for the activation of the myelination program itself in 
addition to, and irrespective of, the role of this factor in cell 
cycle control. 
  c-Jun inhibits myelin gene expression 
  As mentioned in the previous section, c-Jun is expressed consti-
tutively in quiescent cells maintained under basal conditions 
in vitro (  De Felipe and Hunt, 1994  ;   Stewart, 1995  ;   Shy et al., 
1996  ;   Parkinson et al., 2004  ; unpublished data). We took advan-
tage of this to test whether c-Jun inhibits myelin differentia-
tion by comparing Krox-20  –  induced myelin gene expression 
(  Parkinson et al., 2004  ) in normal c-Jun  –  expressing cells with 
that in c  -Jun    –  null cells. Cells were prepared from mice carrying 
a fl  oxed   c-Jun   allele  ( Jun  
fl  /fl    ) and infected in vitro with adeno-
viruses expressing either CRE recombinase to remove   c-Jun   or 
GFP as a control. Western blotting and immunolabeling con-
fi  rmed that   c-Jun   was excised in essentially all cells after infec-
tion with CRE virus (  Fig. 2 A  ). We found that Krox-20  –  induced 
expression of the myelin proteins protein zero (P  0  ) and periaxin 
was strikingly facilitated in   c-Jun  – null  cells  ( Fig.  2,  B – E ).  DNA 
synthesis was essentially absent in both experimental condi-
tions (unpublished data). Similar differences between   c-Jun  –
  null and control cells were obtained when quiescent cells cultured 
in defi  ned medium (DM) were induced to express myelin genes 
by db-cAMP/      –  neuregulin-1 (NRG-1;   Fig. 2, F and G  ). Never-
theless, inhibition of the c-Jun pathway was not suffi  cient to 
trigger myelin differentiation. Without enforced Krox-20 ex-
pression or db-cAMP, neither genetic removal of   c-Jun   nor  ap-
plication of JNK blockers elevated periaxin or P  0   ( Fig.  2  A   and 
not depicted). 
  These experiments indicate that c-Jun is a negative regula-
tor of myelin differentiation. They show that in normal cultured 
Schwann cells, constitutive c-Jun appears suffi  cient to act as a 
break on the transition of quiescent immature Schwann cells to 
the myelin phenotype. The inhibitory effect of c-Jun does not 
depend on enforced overexpression of c-Jun nor is it contingent 
on the role of c-Jun in Schwann cell proliferation. 
  c-Jun inhibits myelin genes without 
N-terminal phosphorylation 
  The experiments discussed in the previous section showed that 
genetic removal of c-Jun amplifi   ed  Krox-20 –   or  cAMP-induced 
myelin differentiation, despite the fact that both agents gradually 
suppress endogenous c-Jun and reduce it to very low levels by 
2  –  3 d (  Parkinson et al., 2004   and above). We then tested whether 
prevention of this down-regulation and maintenance of c-Jun ex-
pression would have the opposite effect and inhibit myelin gene 
activation because this would be the predicted outcome if c-Jun 
acts as a negative regulator of the myelin program. 
  Figure 2.       Genetic removal of c-Jun ampliﬁ  es Krox-20 or cAMP-induced 
myelin protein expression.   (A) Western blot showing that c-Jun is absent 
from   Jun   
ﬂ  /ﬂ     cells infected with CRE-expressing adenovirus. The blot also 
compares periaxin in control (Con) and   c-Jun    –  null cells (CRE) infected with 
GFP control adenovirus (GFP) or a Krox-20/GFP virus (K20). Note high 
periaxin levels in Krox-20  –  infected   c-Jun    –  null cells (CRE). (B  –  E)   c-Jun   con-
trol (  cJun   con) and   c-Jun    –  null mouse Schwann cells 2 d after infection with 
Krox-20/GFP adenovirus. Note that Krox-20 induces much higher levels 
of P  0   protein in   c-Jun    –  null cells (D and E) than in control cells (B and C). 
The reason why P  0   levels in the Krox-20  –  expressing control cells appear 
low in this picture (C) compared with other comparable experiments (e.g., 
  Fig. 4 I  ) is that exposure had to be reduced (equally for C and E) to avoid 
overexposure in E. (F and G) P  0   protein expression in control cells P  0   (  cJun   
con) and c  -Jun    –  null mouse Schwann cells after 3 d of exposure to db-
cAMP/NRG-1. Note that cAMP/NRG-1 induces substantially higher P  0   
levels in cells without c-Jun. Bars, 15   μ  m.     JCB • VOLUME 181 • NUMBER 4 • 2008  628
  MAPK kinase 7 (MKK7) inhibits myelin 
gene expression by elevating c-Jun 
 MKK7  specifi  cally phosphorylates and activates JNK, which 
results in phosphorylation of c-Jun and sometimes in eleva-
tion of the levels of c-Jun protein. This cascade is thought to 
be an important activator of c-Jun signaling in several cell 
types. We therefore tested whether MKK7 would inhibit myelin 
differentiation. 
  By infecting cells with an MKK7-expressing adenovirus, 
we found that MKK7 was a powerful inhibitor of Krox-20  –   or 
db-cAMP  –  induced myelin gene expression (  Fig. 4, A and B  ). 
Enforced MKK7 expression also activated c-Jun in the Krox-20  – 
expressing cells, in which c-Jun would normally be reduced 
to undetectable levels (  Fig. 4, C  –  F  ). Similarly, MKK7 elevated 
c-Jun protein in cells in which c-Jun had been suppressed by 
db-cAMP (see   Fig. 8 C  ). This suggested that MKK7 inhibited 
myelin genes by activating c-Jun. To demonstrate this, we com-
pared the effect of MKK7 in   c-Jun    –  null cells with that in con-
trol cells. As expected from the Western blots (  Fig. 4, A and B  ), 
MKK7 signifi  cantly (P   <   0.001) reduced the number of control 
cells that expressed periaxin in response to Krox-20 (  Fig. 4 G  ). 
Importantly, this inhibitory effect was abolished in   c-Jun  – null 
cells (  Fig. 4 G  ). Therefore, MKK7-mediated inhibition of myelin 
gene expression depends on c-Jun. 
  We also showed that delayed activation of c-Jun could 
reverse P  0   expression, even in cells in which P  0   expression  was 
already established by retroviral expression of Krox-20. We added 
MKK7 adenovirus to activate c-Jun expression in cells that 
were already expressing high levels of P  0  . We found that, de-
spite ongoing Krox-20 expression, MKK7 reversed the effects 
of Krox-20 and reduced P  0   protein levels (  Fig. 4, H  –  K  ; and see 
Materials and methods). 
  In the two previous sections, we showed that basal consti-
tutive levels of c-Jun and enforced expression of Jun molecules 
suppress myelin genes. In this section, we revealed inhibition 
of myelin genes by MKK7/JNK-mediated activation of c-Jun. 
Therefore, all three ways of examining c-Jun signaling agree, 
showing that c-Jun has the potential to negatively regulate my-
elin differentiation. 
  c-Jun activation inhibits myelination 
in dorsal root ganglion (DRG)/Schwann 
cell cocultures 
  If c-Jun is a negative regulator of myelination, enforced acti-
vation of c-Jun in Schwann cells should inhibit myelination in 
DRG/Schwann cell cocultures. We verifi  ed that myelination 
in these cultures was associated with c-Jun down-regulation, 
as seen both in vivo and in response to Krox-20 expression. 
Double immunolabeling of myelinating Schwann cell/DRG 
cultures with antibodies to periaxin and c-Jun confi  rmed that 
  ≥  90% of the periaxin-positive myelinating cells no longer ex-
pressed c-Jun (  Fig. 5, A  –  C  ). The remaining periaxin-positive 
cells showed weak c-Jun labeling, perhaps refl  ecting subopti-
mal conditions for myelination in vitro because c-Jun  –  positive 
nuclei are not seen in myelinating cells of normal nerves in vivo. 
To determine whether enforced c-Jun expression inhibits mye-
lination, Schwann cells were retrovirally infected with either 
exogenous Jun proteins from both constructs was fully main-
tained in spite of cotransfection with Krox-20 (unpublished data). 
  This shows that effective induction of myelin genes by 
Krox-20 depends on Krox-20 simultaneously suppressing c-Jun. 
If this is prevented by enforcing sustained expression of Jun 
molecules, myelin gene expression is blocked or severely reduced. 
Notably, this inhibition of myelin genes does not appear to 
depend on phosphorylation of c-Jun. 
  Figure 3.       Persistent expression of c-Jun inhibits Krox-20  –  induced myelin 
protein expression.   (A and B) Cotransfection of Krox-20/GFP with Jun(Asp) 
or with Jun(Ala) inhibits Krox-20  –  mediated induction of periaxin and P  0  . 
K20/EV represents cells cotransfected with Krox-20 and control vector. 
(C  –  F) P  0   in situ experiment showing that cotransfection of Krox-20/GFP 
with Jun(Ala) inhibits Krox-20  –  mediated induction of   P  0     mRNA. C and D 
are controls, and the arrows show a cell coexpressing Krox-20 and a con-
trol vector where Krox-20 has induced P  0   mRNA. Arrows in E and F show 
a cell coexpressing Krox-20 and Jun(Ala) where Jun(Ala) has inhibited 
Krox-induced   P  0     expression. Bar, 15   μ  m. (G) Percentages of GFP-positive 
cells that also express   P  0     mRNA in cells cotransfected with the constructs 
indicated. Error bars show one standard deviation of the mean.     629   C  -J  UN   REPRESSES MYELINATION   •   Parkinson et al.
empty vector (BP2) or vector expressing a c-Jun  –  estrogen re-
ceptor fusion protein (BP2/cJunER), in which the transcrip-
tional activity of c-Jun can be activated by the addition of 
4-hydroxytamoxifen (  Bossy-Wetzel et al., 1997  ). 2 wk after 
seeding purifi  ed neurons with either control (BP2) or cJunER-
expressing (BP2/cJunER) cells, the cocultures were induced 
to myelinate by addition of ascorbate in the presence of 10 
   7  
M 4-hydroxytamoxifen to activate the cJunER protein. 2 wk 
later, the cultures were immunolabeled for myelin basic pro-
tein (MBP) to identify myelinating cells, and the total number 
of myelinating Schwann cells per coverslip was counted. We 
found that activation of c-Jun signifi  cantly (P   <   0.01) inhibited 
myelination (  Fig. 5 D  ). In related experiments, we also in-
duced c-Jun in DRG/c-JunER Schwann cell cocultures with 
tamoxifen, 2 wk after ascorbate had been added to induce my-
elination. In this case too there was a substantial reduction in 
the number of myelin segments relative to that seen in control 
cultures without tamoxifen, indicating that induction of c-Jun 
  Figure 4.       MKK7 inhibits myelin gene expression in a c-Jun  –  dependent way.   
(A) Western blot showing that MKK7, presumably by activating JNK, 
inhibits Krox-20  –  induced myelin protein expression. The cells were co-
infected with adenoviruses expressing the constructs indicated. (B) Western 
blot of cells infected with adenoviruses expressing control LacZ or activated 
MKK7 to activate JNK. Note that periaxin induced by 2 d of exposure to 
1 mM of db-cAMP in LacZ control cells is inhibited by MKK7 expression. 
(C  –  F) MKK7 activates c-Jun even in the presence of Krox-20. C and E show 
that Krox-20 coinfected with a control LacZ-expressing adenovirus sup-
presses c-Jun levels. D and F show that when Krox-20 is coexpressed with 
MKK7, high c-Jun levels are maintained. (G) MKK7-mediated suppression 
of myelin gene expression depends on c-Jun. In normal cells (  cJun   con), 
Krox-20  –  induced periaxin expression (K20/LacZ) is suppressed by MKK7 
(K20/MKK7). This suppression does not occur when this experiment is re-
peated in cells without c-Jun (  cJun   null). Error bars show one standard devi-
ation of the mean. (H  –  K) Reactivation of JNK/c-Jun in Krox-20  –  expressing 
cells that already synthesize P  0   abolishes P  0   protein expression. Retrovirally 
infected cells already expressing Krox-20 and P  0   were infected with either 
LacZ control (H and I) or MKK7-expressing (J and K) adenoviruses. Cells 
were labeled with either LacZ and P  0   (H and I) or MKK7 and P  0   (J and K) 
antibodies. Note down-regulation of P  0   protein in Krox-20  –  expressing cells 
infected with MKK7 adenovirus. Bars, 15   μ  m.     
  Figure 5.       c-Jun expression inhibits myelination in Schwann cell/DRG 
neuron cocultures.   (A and B) c-Jun is down-regulated in myelinating cells. 
Arrows show c-Jun  –  negative nuclei in periaxin-positive (red) myelinating 
cells. Numerous other cells that are not forming myelin remain c-Jun posi-
tive (green). (C) Western blot showing expression of endogenous c-Jun and 
cJunER fusion protein in puriﬁ  ed Schwann cells retrovirally infected with ei-
ther control empty vector (BP2) or vector expressing the cJunER fusion pro-
tein (BP2/cJunER). (D) The number of myelinating segments in cocultures is 
reduced by c-Jun expression (cJun ER). Error bars show one standard devia-
tion of the mean. (E and F) In cocultures, c-Jun is reactivated in myelinating 
cells induced to demyelinate by high concentrations of NRG-1. (E) Control 
cultures with arrows showing c-Jun  –  negative nuclei associated with peri-
axin-positive (red) myelinating cells. Arrowhead shows c-Jun (green) in a 
nucleus not associated with myelinating cells. (F) Cultures exposed to 
200 ng/ml NRG-1 for 3 d. Arrow shows activation of c-Jun in a degenerat-
ing myelin internode and arrowhead indicates c-Jun in a nucleus of a cell 
not engaged in myelin formation. Bars, 15   μ  m.     JCB • VOLUME 181 • NUMBER 4 • 2008  630
can exert effects both early and late in the myelination pro-
gram (see Materials and methods). 
  Exposure of DRG/Schwann cell cocultures to high con-
centrations of NRG-1 provides a demyelination signal and results 
in fragmentation of myelin internodes (  Zanazzi et al., 2001  ). 
Using 200 ng/ml NRG-1 to confi  rm this, we found that the de-
myelination was accompanied by extensive increase in nuclear 
c-Jun expression, with     60% of identifi  able myelin internodes 
now showing clear nuclear c-Jun expression (  Fig. 5, E and F  ). 
This observation is consistent with c-Jun providing a signal 
that opposes myelin differentiation and promotes the imma-
ture Schwann cell phenotype. Collectively, these observations 
strengthen the conclusion that c-Jun is a negative regulator of the 
myelin program (  Parkinson et al., 2004  ). 
  A central role for c-Jun in promoting 
dedifferentiation 
  When actively myelinating cells in developing nerves are re-
moved from axonal contact, for example, by preparing dissoci-
ated cell cultures from neonatal nerves, not only is myelination 
arrested but cells revert to the immature phenotype: c-Jun re-
appears, Krox-20 levels fall, and cells stop expressing myelin 
genes and reactivate genes characteristic of immature Schwann 
cells (  Jessen and Mirsky, 2005  ). Because c-Jun potentially 
blocks the forward transition toward myelination, we investi-
gated whether c-Jun was also required for, or promoted, the re-
verse transition back to the immature phenotype. This possibility 
was also raised by two previous observations, namely the re-
activation of c-Jun in demyelinating cocultures and the fi  nding 
that delayed activation of c-Jun reversed myelin gene expression 
already established through enforced Krox-20 expression. 
  To test this, we examined the rate of dedifferentiation of 
neonatal myelinating cells in the absence of c-Jun. To obtain such 
cells, we used   c-Jun    –  null Schwann cells from mice in which 
fl  oxed   c-Jun   ( Jun  
fl/fl  ) had been excised in Schwann cells se-
lectively by breeding with   P  0 -CRE   mice (see Materials and 
methods). No obvious morphological or immunohistochemical 
abnormalities were noted in these nerves by a morphological 
  Figure 6.       Neonatal myelinating cells dedifferentiate slowly in the absence 
of c-Jun.   (A and B) Comparison of P  0   expression in control cells from   c-Jun   
ﬂ  /ﬂ    /
  CRE   
        (cJun   con) mice and cells without c-Jun from   c-Jun   
ﬂ / ﬂ   /  CRE   
+   (  cJun   
null) mice prepared at P5 and cultured in DM containing 20 ng/ml NRG-1 
for 4 d. (A) Cells with high myelination-related levels of P  0   have largely dis-
appeared from control cultures. (B)   c-Jun    –  null cultures retain numerous cells 
with high P  0  , two of which are illustrated. (C  –  F) Similar delay in the loss 
of periaxin in cells prepared at P2 from nerves of   cJun    –  null mice cultured 
for 2 d (see Materials and methods). (C and D) Control cultures are c-Jun 
positive and periaxin has largely disappeared. (E and F)   c-Jun    –  null cultures 
are c-Jun negative and retain a large number of strongly periaxin-positive 
cells. (G and H) Similar experiments with cells from   JunAA   mice. These 
cells lose periaxin expression at the same rate as control cells, indicating 
that the major N-terminal phosphorylation sites of c-Jun are not needed for 
suppression of periaxin. Bar, 15   μ  m. (I) Quantiﬁ  cation of the results illus-
trated in C  –  H. The graph shows the number of periaxin-positive cells (rela-
tive to the number 3 h after plating) in   c-Jun   control,   c-Jun    –  null and   JunAA   
cells after 2, 4, and 6 d in DM   ±   20 ng/ml NRG-1. (J) mRNA for myelin 
genes disappears only slowly from c-Jun  –  null cells. Schwann cells puriﬁ  ed 
from control, c-Jun  –  null, and JunAA P3 mice were plated for 48 h in DM 
before RNA was extracted and levels of myelin markers were analyzed by 
quantitative PCR. Relative expression levels of c-Jun, MBP, periaxin, and P  0   
(MPZ) were obtained by normalizing samples to GAPDH. The data were 
then expressed as a percentage of the maximum (1) for each of the four 
genes. The difference in MBP, P  0  , and periaxin mRNA levels between 
c-Jun control and null mice was signiﬁ  cant (P   <   0.01). The same applies to 
the differences between JunAA and null mice. The dataset for each gene 
was analyzed by one-way ANOVA and Tukey  ’  s Multiple Comparison test 
where appropriate (using GraphPad Prism Software). Error bars show one 
standard deviation of the mean. AU, arbitrary units.     
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examination (and adult nerves contained the expected numbers of 
apparently normal myelinated and unmyelinated fi  bers; unpub-
lished data). Actively myelinating cells were removed from axo-
nal contact by dissociating neonatal nerves (postnatal day [P] 
2  –  5) and plating the cells in culture. In wild-type cultures, c-Jun, 
which had been down-regulated in myelinating cells, was rapidly 
reexpressed after plating and seen in the large majority of my-
elinating cells by 6 h, whereas cultures from c-Jun  –  null animals 
were essentially c-Jun negative (unpublished data). In other cul-
tures maintained for 5 – 7 d, immunolabeling showed that 100% of 
control cells ( Jun  
fl  /fl   ;  P  0 -CRE  
    ) had c-Jun – positive nuclei, whereas 
  ≤  5% of cells from   c-Jun  – null  mice  ( Jun  
fl  /fl   ;   P  0 -CRE  
+ )  expressed 
c-Jun, indicating effective removal of c-Jun. NRG-1 was included 
in the medium in some experiments because NRG-1 signaling is 
up-regulated in cut nerves and has been implicated in the promo-
tion of Schwann cell dedifferentiation after injury (  Carroll et al., 
1997  ;   Kwon et al., 1997  ;   Cheng et al., 1998  ;   Zanazzi et al., 2001  ; 
  Guertin et al., 2005  ). We found that the rate of loss of the myelin-
associated proteins periaxin and P  0   was strongly delayed in   c-Jun  –
  null cultures compared with   c-Jun –   positive controls (  Fig. 6, A  –  F 
and I  ). A similar delay was seen when mRNA levels for periaxin, 
P  0  , and MBP were examined in these cultures by quantitative 
RT-PCR (  Fig. 6 J  ). Therefore, when early myelinating cells are 
removed from axons, the rapid reactivation of c-Jun pushes the 
cells toward the immature phenotype. 
  N-terminal phosphorylation of c-Jun is not required for in-
hibition of myelin differentiation (  Fig. 3  ). In agreement with this, 
Schwann cells from homozygous   JunAA   mice, in which the ma-
jor N-terminal phosphorylation sites (serine-63 and -73) of both 
  c-Jun   alleles have been mutated to nonphosphorylatable alanine 
(  Behrens et al., 1999  ), dedifferentiated at a similar rate to that of 
control cells (  Fig. 6, G  –  I  ). This was confi  rmed at the mRNA level 
using quantitative RT-PCR (  Fig. 6 J  ). Thus, the activity of the 
c-Jun protein drives myelinating cells toward the immature pheno-
type without requiring N-terminal phosphorylation. 
  These experiments show that c-Jun has a role in sending 
actively myelinating cells back to the immature phenotype 
when the cells are removed from axonal contact in vitro. To test 
whether c-Jun also acted in this way in vivo, we cut the sciatic 
nerves of 5-d-old conditional   c-Jun  – null  ( Jun  
fl  /fl   ;   P  0 -CRE  
+ )  and 
control (  Jun  
fl  /fl   ;   P  0 -CRE  
     ) mice and compared the rate of myelin 
loss as a measure of dedifferentiation. Morphologically, this 
was done by counting the number of rounded or collapsed 
myelin sheaths that remained at 3 and 5 d after the operation. 
The results were confi  rmed by measuring the disappearance 
of MBP, using immunolabeling and image analysis of trans-
verse nerve sections at 2, 3, and 5 d (  Fig. 7  ;   Perry et al., 1995  ). 
Both measures showed a marked delay of myelin loss in the 
  c-Jun    –  null nerves. Thus, c-Jun, when reexpressed after injury, 
promotes dedifferentiation in vitro and in vivo. 
  Figure 7.       c-Jun drives dedifferentiation in vivo.   (A) MBP immunolabeling 
of sciatic nerve sections showing delayed loss of myelin in   c-Jun    –  null nerves 
compared with controls, 3 d after transection of nerves of 5-d-old mice. 
Bar, 10   μ  m. (B) Quantiﬁ  cation of the delay in myelin disappearance by 
quantitative image analysis of MBP-immunolabeled sections (comparable 
to those shown in A) 2, 3, and 5 d after injury (expressed as percentage 
of MPB 
+   area in uncut P5 nerve). In every case, the difference between 
c-Jun  –  null and control nerves is signiﬁ  cant (P   <   0.01). (C) Electron micro-
graphs showing   c-Jun    –  null and control nerves from 5-d-old mice, intact and 
3 d after injury as indicated. Note preservation of rounded or partially 
collapsed myelin sheaths in   c-Jun    –  null nerves. Bar, 4   μ  m. (D) Counts of my-
elin sheaths (rounded or collapsed) in c  -Jun    –  null and control nerves 3 and 
5 d after injury (3 d, P   <   0.05; 5 d, P   <   0.01). Error bars show standard 
deviation of the mean.     
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  Figure 8.       Cross-inhibitory relationship between c-Jun and Krox-20.   
(A and B) Cells cotransfected with empty GFP vector (to visualize transfected 
cells) and an empty control vector (EV; A) or a   Jun(Asp)   vector (B). Both 
cultures were then treated with 1 mM db-cAMP for 2 d to induce Krox-20 
and were immunolabeled for Krox-20. In A, arrows point to induced Krox-20 
in nuclei of GFP-positive control cells (yellow nuclei of Krox-20  –  positive 
GFP-positive cells). In B, no Krox-20 is induced (arrows) in cells containing 
  Jun(Asp)  . Arrowheads in both panels indicate untransfected cells that have 
been induced to express Krox-20 by db-cAMP as controls for induction. 
(C) Activation of JNK inhibits induction of Krox-20. Western blot of cells 
infected with adenovirus expressing control LacZ or virus expressing acti-
vated MKK7 to activate JNK is shown. Note that the Krox-20 and periaxin 
induced by 2 d of exposure to 1 mM db-cAMP in LacZ control cells is 
inhibited by MKK7 expression. Note also that MKK7 elevates c-Jun in the 
presence of db-cAMP. (D  –  G) In   c-Jun    –  null cells, loss of Krox-20 expression 
is signiﬁ  cantly delayed. Double immunolabeling of   c-Jun   control cells (D 
and E) and   c-Jun    –  null cells (F and G) for Krox-20 (red) and periaxin (green) 
after 2 d in culture in DM containing 20 ng/ml NRG-1 is shown. Note that 
Krox-20 has disappeared from the control cells, whereas many   c-Jun    –  null 
cells still have Krox-20  –  positive nuclei (G, arrows). Note that   c-Jun    –  null 
Krox-20  –  positive cells are also periaxin positive (F, arrows), whereas con-
trol cells have lost periaxin expression (D). Bars, 15   μ  m.     
  A cross-inhibitory relationship between 
c-Jun and Krox-20 
  The fact that Krox-20 and c-Jun have opposing effects on my-
elination and that Krox-20 suppresses c-Jun raised the question 
of whether c-Jun, in turn, suppressed Krox-20 because cross-
inhibitory relationships between transcription factors involved 
in fate determination have been described in other systems. 
We found that c-Jun suppressed Krox-20 in several types of 
experiment. First, enforced c-Jun expression in wild-type cells, 
using   Jun(Asp)   or   Jun(Ala)  , completely blocked Krox-20 ex-
pression in response to db-cAMP elevation (  Fig. 8, A and B  ; and 
not depicted). Second, db-cAMP  –  induced Krox-20 expression 
was blocked when c-Jun was activated by enforced expression 
of the upstream kinase MKK7 and the results were analyzed 
by Western blot (  Fig. 8 C  ). Note that MKK7 also prevented the 
db-cAMP  –  induced down-regulation of c-Jun protein and phospho  –
  c-Jun. Lastly, we examined the loss of Krox-20 that is seen 
when neonatal myelinating cells are removed from axonal con-
tact and placed in culture (  Fig. 8, D  –  G  ). When cells from con-
trol P2 nerves were plated in DM, Krox-20 protein expression 
disappeared within 24 h as expected. But when cells from 
  c-Jun    –  null nerves were used, robust Krox-20 immunoreactivity 
remained in many cells at 2 d (  Fig. 8 G  ), although Krox-20 
  immunolabeling decreased and eventually disappeared there-
after (not depicted). Therefore, when myelinating cells from 
normal neonatal nerves lose axonal contact, the resulting reacti-
vation of c-Jun (above) contributes signifi  cantly to the rapid drop 
in Krox-20 that is seen under these circumstances. 
  Thus c-Jun suppresses Krox-20 expression in several situa-
tions. In contrast, we found that c-Jun did not suppress the my-
elin-related transcription factor Oct-6, which appears earlier than 
Krox-20 in developing nerves and controls the timing of Krox-20 
activation, although its expression is not restricted to myelinating 
Schwann cells (  Bermingham et al., 1996  ;   Blanchard et al., 1996  ; 
  Jaegle et al., 1996  ). Enforced expression of MKK7 to activate 
c-Jun did not signifi  cantly suppress db-cAMP  –  induced Oct-6 ex-
pression (  Fig. 9 A  ). Also, phospho  –  c-Jun and Oct-6 were co-
expressed by Schwann cells before myelination (  Fig. 9, B  –  E  ). 
Coexpression of c-Jun and Krox-20 is seen neither in these cells 
nor later in development, when c-Jun is selectively lost from 
cells that activate Krox-20 and myelinate ( Parkinson et al., 2004 ). 
Onset of myelination therefore involves a transition from imma-
ture cells coexpressing Oct-6 and c-Jun to myelinating cells that 
are c-Jun negative but coexpress Oct-6 and Krox-20, although 
Oct-6 disappears later from most myelinating cells. 
  Krox-20 and c-Jun regulate Sox-2 
  Because Sox-2 has been implicated in negative regulation of 
myelination (  Le et al., 2005b  ), we examined whether Sox-2 and 
c-Jun were coexpressed and whether Sox-2 was suppressed by 
cAMP or Krox-20, as expected of a negative myelin regulator. 
We found that Sox-2 and c-Jun were coexpressed in the nuclei 
of immature Schwann cells that have not yet myelinated (  Fig. 10, 
A  –  D  ) and were reactivated and coexpressed after injury (  Fig. 10, 
G  –  N  ; and not depicted). In vitro, db-cAMP or enforced Krox-20 
suppressed Sox-2 (  Fig. 10, E and F  ). Thus, db-cAMP and Krox-20 
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activation drives the cells back to the immature state. Also in vivo, 
reactivation of c-Jun after injury of neonatal nerves pushes early 
myelinating cells toward demyelination. In previous work, we 
also showed that c-Jun is important for events that characterize the 
immature but not myelinating state, namely cell death and pro-
liferation (  Parkinson et al., 2004  ). 
  The most striking abnormality in early postnatal nerves 
in conditional   c-Jun    –  null mice is the failure of myelinating 
cells to dedifferentiate normally after injury. It is therefore 
likely that the negative infl  uence of c-Jun on myelin differen-
tiation that we have documented is, in vivo, more important 
for pushing the dedifferentiation program in injured or patho-
logical nerves than for the regulation of myelination during 
normal development. 
  Consistent with the involvement of Krox-20 and c-Jun in 
antagonistic programs, expression of these factors is mutually 
exclusive: immature cells express relatively high levels of c-Jun 
and low levels of Krox-20, switching to high levels of Krox-20 
and low levels of c-Jun in myelinating cells. In cut or crushed 
nerves, Krox-20 falls and c-Jun is reexpressed at high levels 
as cells transit back to the immature state. Furthermore, c-Jun 
and Krox-20 show a cross-antagonistic functional relationship 
because expression of Krox-20 suppresses c-Jun and enforced 
expression of c-Jun suppresses Krox-20. 
  c-Jun is therefore a transcription factor that negatively 
regulates the myelinating Schwann cell phenotype, representing 
a signal which functionally stands in opposition to the network 
of promyelin transcription factors, which includes Oct-6, Brn2, 
NF    B, Sox-10, and Nab1 and 2, in addition to the key role of 
Krox-20 (  Topilko et al., 1994  ;   Nagarajan et al., 2001  ;   Jaegle et al., 
2003  ;   Le et al., 2005b  ;   Ghislain and Charnay, 2006  ;   LeBlanc et al., 
2006  ). Negative regulation of myelin differentiation is likely to 
emerge as a major aspect of Schwann cell biology, with particu-
lar importance for plasticity, demyelinating pathology, and re-
sponses to injury and regeneration, in addition to developmental 
regulation. It is also likely that the molecular machinery of my-
elin suppression will turn out to be equally complex to that of its 
promyelin counterpart. Thus, inducible nitric oxide synthase, 
Sox-2, Erk1/2 activation, and Notch signaling have all been im-
plicated in negative control of myelin differentiation ( Harrisingh 
et al., 2004  ;   Ogata et al., 2004  ;   Le et al., 2005a  ;   Agthong et al., 
2006 ; Woodhoo, A., M. Duran, K.R. Jessen, and R. Mirsky. 2004. 
  Differentiation  . Abstr. 119). Similarly, the p38 MAPK signaling 
pathway, although important for events immediately before my-
elination, also accelerates demyelination (  Fragoso et al., 2003  ; 
unpublished data), and delayed demyelination is seen in mice 
with genetic inactivation of Toll receptors, nitric oxide synthase, 
phospholipase A2, and matrix metalloprotease 9 ( Levy et al., 2001 ; 
  De et al., 2003  ;   Shubayev et al., 2006  ;   Boivin et al., 2007  ). In fu-
ture work, it will be important to learn about the functional 
interactions between the different signaling systems that are 
emerging as potential myelin suppressors. 
 We  fi nd that Krox-20 represses both c-Jun and Sox-2 and 
that, in the absence of Krox-20, c-Jun is highly expressed in 
Schwann cells without the need for specifi  c extrinsic signaling. 
Therefore, the loss of Krox-20 that follows nerve cut or crush 
is likely to allow the cells to resume their constitutive c-Jun 
  In c-Jun  –  null cells generated by CRE expression in vitro, 
Sox-2 protein levels were reduced (  Fig. 10 O  ). In accord with 
this, inhibition of JNK (which controls c-Jun levels;   Figs. 4 and 8  ) 
by the inhibitor SP600125 or by adenoviral expression of the 
JNK binding domain of JIP-1 also reduced Sox-2 protein ex-
pression (  Fig. 10 P   and not depicted). Sox-2 remaining in cul-
tures of   c-Jun    –  null cells was suppressed to undetectable levels 
by enforced Krox-20 expression (  Fig. 10 Q  ). 
  Collectively, these experiments show that c-Jun and Sox-2 
are extensively coregulated. They are consistent with the possi-
bility that c-Jun plays a role in regulating Sox-2 and that some 
of the inhibitory effects of c-Jun on myelination may be chan-
neled through Sox-2. 
  Discussion 
  Much as Krox-20 promotes the transition from the immature 
Schwann cell phenotype toward myelination, we fi  nd that c-Jun 
acts in a reverse way to promote the immature Schwann cell state 
at the expense of myelination. c-Jun, at physiological expression 
levels and apparently without N-terminal phosphorylation, in-
hibits myelin gene activation by Krox-20 or cAMP elevation. 
Enforced c-Jun expression also inhibits myelination in cocultures. 
When early myelinating cells are released from axon-associated 
promyelin signals and placed in culture, the resulting c-Jun 
  Figure 9.       The JNK  –  c-Jun pathway does not suppress Oct-6.   (A) West-
ern blot of Schwann cells infected with adenoviruses expressing control 
LacZ or activated MKK7 to activate JNK. Note comparable induction of 
Oct-6 (by 1 mM db-cAMP for 24 h) in control cells and MKK7 cells. (B  –  E) 
Teased E17 sciatic nerve stained with HOECHST dye showing that Oct-6 
and phospho  –  c-Jun are coexpressed in immature Schwann cells. (B and C) 
Double immunolabeling for phospho  –  c-Jun (P-cJun; red) and Oct-6 (green) 
in C shows coexpression in Schwann cell nuclei. (D and E) Double immuno-
labeling for phospho  –  c-Jun (red) and Krox-20 (green) in E shows phos-
pho  –  c-Jun alone. Bar, 15   μ  m.     JCB • VOLUME 181 • NUMBER 4 • 2008  634
  expression. This will help push the cells toward dedifferentia-
tion and promote proliferation as seen in Wallerian degenera-
tion. A similar mechanism is likely to be operative during the 
dedifferentiation and proliferation that takes place when Krox-20 
is genetically inactivated in adult nerves without axon transec-
tion (  Decker et al., 2006  ). The way in which c-Jun and Sox-2 
interact during these events remains to be examined. 
  Although we have shown previously that in Schwann cells, 
as in other cell types, c-Jun has a role in controlling prolifera-
tion (  Parkinson et al., 2004  ), this effect can be clearly dissoci-
ated from the negative regulation of myelin differentiation. 
Several of the present experiments demonstrate this, including 
those in which genetic removal of c-Jun amplifi  es myelin gene 
expression in response to Krox-20 or cAMP and where myelin 
gene activation by these signals is inhibited by enforced expres-
sion of Jun or JNK activation by MKK7. It is also seen when 
clearance of Krox-20 and myelin proteins from early myelinat-
ing cells that have been removed from axons and placed in DM 
is accelerated by c-Jun or JunAA. In all these cases, Jun inhibits 
myelination or drives demyelination under conditions where 
Schwann cells are not dividing. 
  Suppression of myelination by c-Jun can also be dissoci-
ated from the classical N-terminal phosphorylation of c-Jun 
typically performed by JNK. Rather, suppression of the myelin 
phenotype appears to depend on the levels of the c-Jun protein 
itself. This can be seen from the fact that Jun(Ala), in which all 
potential N-terminal phosphorylation sites are absent, suppressed 
Krox-20  –  induced myelin gene expression as effectively as 
Jun(Asp), in which the N-terminal phosphorylation sites have 
been mutated to aspartic acid to mimic the active phosphorylated 
c-Jun. It is also evident from the observation that normal c-Jun 
and nonphosphorylatable c-Jun (in cells from   JunAA   mice)  ap-
pear to be equally effective at driving down myelin gene ex-
pression in experiments where neonatal myelinating cells are 
removed from axonal contact and placed in culture. This is in 
line with results from other systems, where phosphorylation of 
c-Jun by JNK is not required for all its actions (  Behrens et al., 
1999  ;   Raivich and Behrens, 2006  ). The JNK pathway may in-
stead function to control c-Jun protein levels, in part by modu-
lating the activity of several transcription factors that together 
regulate the   c - jun   promoter (  Besirli et al., 2005  ), which is a situ-
ation that would explain the effects of the JNK activator MKK7 
in our experiments. 
  In injured nerves, loss of myelin differentiation is a bene-
fi  cial response that helps axonal regeneration and repair. But the 
loss of myelin differentiation in demyelinating neuropathies, 
such as Charcot-Marie-Tooth 1A and Guillain-Barr  é   syndrome, 
is unhelpful and leads to disability. From a clinical standpoint, 
it will be important to determine whether c-Jun is a component 
of the mechanism that pushes myelinating cells toward de-
myelination in these pathological conditions because this would 
open new avenues for clinical intervention. 
  Figure 10.       Regulation of Sox-2 by Krox-20 and c-Jun.   (A  –  D) Immuno-
labeling of teased newborn sciatic nerve. Nuclear c-Jun is in premyelinating 
cells (  Parkinson et al., 2004  ), most of which also express Sox-2 (over-
lay). (E) db-cAMP down-regulates Sox-2 protein. Western blot of control 
untreated cells (Con) and cells treated with 1 mM db-cAMP for 3 d (cAMP) 
is shown. Note down-regulation of c-Jun and Sox-2 and increase in Oct-6 
and Krox-20. (F) Krox-20 down-regulates Sox-2 and c-Jun. Western blot of 
cells 3 d after infection with either GFP control (GFP) or Krox-20 (K20) adeno-
viruses. (G  –  N) c-Jun and Sox-2 are coexpressed after nerve injury. Double 
immunolabeling of a teased uncut nerve (G  –  J) and of the distal stump of 
a nerve 3 d after transection (K  –  N). Note that neither c-Jun nor Sox-2 are 
expressed in intact nerve, whereas both factors are activated by injury 
and found in the same nuclei (arrows). Bars, 15   μ  m. (O) Sox-2 protein 
is reduced in   c-Jun    –  null cells. Western blot of mouse   Jun   
ﬂ  /ﬂ     Schwann cells 
infected with either GFP control (GFP) or CRE-recombinase (CRE) adeno-
viruses. Note reduced levels of Sox-2 in CRE recombined cells. (P) Inhibition 
of JNK reduces Sox-2 protein levels. Western blot for Sox-2 in control 
cells (Con) and cells treated for 2 d with 30   μ  M SP600125 JNK inhibitor 
(+SP6). (Q) Western blot showing that enforced Krox-20 expression sup-
presses residual Sox-2 in c-Jun  –  null cells. Control cells (Con) and   c-Jun    –  neg-
ative cells (CRE) were infected with control adenovirus (GFP) or adenovirus 
expressing Krox-20 (K20). Note the two-step reduction in Sox-2, ﬁ  rst by 
removing   c-Jun   alone (GFP and CRE) and second by expressing Krox-20 
from   c-Jun    –  null cells (K20 and CRE).     
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experiment was performed in triplicate, and data are from four indepen-
dent experiments. 
  In other experiments, we added tamoxifen 10  –  14 d after c-JunER 
Schwann cells had been induced to myelinate by addition of ascorbate. 
The tamoxifen was added for 4  –  6 d before ﬁ  xation and immunolabeling 
for MBP. In this case also there was a substantial reduction in the number 
of myelin segments relative to control cultures, indicating that induction of 
c-Jun is able to exert effects both early and late in the myelination program. 
In two experiments, with a total of 10 experimental and 10 control cover-
slips, the mean reduction in the total number of myelin segments was 
92.1% in cultures to which tamoxifen had been added. In related experi-
ments, we also showed that delayed activation of c-Jun could reverse Krox-20  – 
induced P  0   expression in cultured c-JunER Schwann cells in which P  0   
expression was already established by adenoviral expression of Krox-20. 
Cells expressing cJunER were infected with Krox-20 adenovirus and c-Jun 
was activated 3 d later by addition of tamoxifen for 3 d before ﬁ  xation and 
immunolabeling with P  0   antibodies. In two experiments with triplicate 
coverslips, we found that despite ongoing Krox-20 expression, tamoxifen 
induction of c-Jun lowered already induced P  0   protein levels from 64.7 
to 34.8%. 
  For DRG explant cultures, DRG were dissected from rat E15 em-
bryos and placed on PDL/laminin-coated coverslips in DM supplemented 
with 0.5% FCS and 50 ng/ml NGF. Cultures were maintained for 2 wk be-
fore the addition of 50 ng/ml ascorbate and for a further 2 wk to induce 
basal lamina formation and myelination. After this time, the cultures were 
ﬁ  xed and immunolabeled with antibodies against P  0   or MBP. 
  Myelin protein down-regulation assays 
  Schwann cells from   c-Jun   
ﬂ  /ﬂ    /  CRE 
        (cJun con) mice and cells without c-Jun 
from   c-Jun   
ﬂ  /ﬂ    /  CRE 
+     (cJun null) mice, from animals aged between P2  –  5, 
were plated on PDL/laminin-coated coverslips. 3 h after plating, time zero 
coverslips were ﬁ  xed and immunolabeled. Sister cultures were topped up 
with DM alone or DM supplemented with 20 ng/ml NRG-1. Coverslips 
were then ﬁ  xed and immunolabeled at the time points stated in the text. 
For quantitative evaluation of the number of periaxin-positive cells in c-Jun 
control and c-Jun  –  null cells at various time points after culturing, the number 
of periaxin-positive cells per coverslip was counted and expressed as a 
percentage of the number at time zero. 
  Quantitative RT-PCR 
  Schwann cells from   P  0  -CRE 
+  /Jun   
ﬂ  /ﬂ     and   P  0  -CRE 
-  /Jun   
ﬂ  /ﬂ     nerves were dissoci-
ated and plated on to PDL/laminin-coated 35-mm dishes as described in 
the previous section. At 3 h after plating, some dishes were used for RNA 
extraction (time zero control). Experimental cells were taken for RNA ex-
traction at 48 h after plating. RNA was puriﬁ  ed using the RNeasy plus kit 
(QIAGEN) and 1.5   μ  g RNA was converted to cDNA using the Superscript II 
ﬁ  rst-strand synthesis system (Invitrogen). Real-time PCR was performed 
using the DyNAmo SYBR Green qPCR kit (Finnzymes) and the Opticon 2 
DNA Engine (MJ Research). Relative expression values were obtained by 
normalizing to GAPDH for each data point. 
  Primer sequences for genotyping and quantitative RT-PCR 
    c-Jun   
ﬂ     mice.     Forward, CCGCTAGCACTCACGTTGGTAGGC; and reverse, 
CTCATACCAGTTCGCACAGGCGGC. 
    P  0  -CRE   mice.     Forward, GCTGGCCCAAATGTTGCTGG; and reverse, 
CCACCACCTCTCCATTGCAC. 
  Quantitative RT-PCR.     GAPDH forward, TGCACCACCAACTGCT-
TAG; GAPDH reverse, GGATGCAGGGATGATGTTC; KROX20 forward, 
AGCTGCCTGACAGCCTCTAC; KROX20 reverse, GTTTCTAGGCGC  A-
GAGATGG; MBP forward, ACACAAGAACTACCCACTACGG; MBP 
reverse, GGGTGTACGAGGTGTCACAA; Periaxin forward, GACTCACC-
GGCAGCTAAGAG; Periaxin reverse, GCCCTTCATCTCGTATCCAG; cjun 
forward, ACCCCCACTCAGTTCTTGTG; cjun reverse, AGTTGCTGAG-
GTTGGCGTAG; P  0   forward, CTGGTCCAGTGAATGGGTCT; and P  0   re-
verse CATGTGAAAGTGCCGTTGTC. 
  Imaging 
  Immunolabeled coverslips were analyzed at room temperature with micro-
scopes (Eclipse E8000 or Optiphot-2; Nikon) or using Plan Fluor 20  ×   0.5, 
40  ×   0.75, 40  ×   1.3, or 40  ×   1.3 NA oil objectives. Images were acquired 
using a digital camera (DZM 1200; Nikon) and Act-1 acquisition software 
(Nikon). Images were processed using Photoshop (version 7.0 or 9.0; Adobe). 
A confocal microscope (Multi-photon UV; Leica) with constituent software 
and a Plan-Apochromat 40  ×   oil objective was used at room temperature to 
acquire images of MBP-immunopositive areas in 5-  μ  m wax-embedded 
  Materials and methods 
  HA-tagged Jun(Asp)- and Jun(Ala)-expressing plasmids were obtained from 
Dirk Bohmann (University of Rochester Medical Center, Rochester, NY; 
  Papavassiliou et al., 1995  ). The cJunER fusion protein construct was obtained 
from Moshe Yaniv (Centre National de la Recherche Scientiﬁ  que Institute 
Pasteur, Paris, France;   Bossy-Wetzel et al., 1997  ). The JNK inhibitor 
SP600125 (  Bennett et al., 2001  ) was obtained from BIOMOL Interna-
tional, L.P. NGF was obtained from Invitrogen. Oct-6 antibodies were ob-
tained from Dies Meijer (Erasmus University Medical Center, Rotterdam, 
Holland) and John Bermingham (McLaughlin Research Institute, Great 
Falls, Montana) and periaxin antibodies were obtained from Peter Brophy 
and Diane Sherman (Centre for Neuroscience Research, Edinburgh, Scot-
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Cell Signaling Technology. Polyclonal MKK7 antibodies and monoclonal 
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transverse sections of degenerating nerve segments. The quantitative anal-
ysis of MBP-positive ﬂ  uorescent areas was then performed using Image J 
image analysis software (National Institutes of Health-). 
  Distal stumps of transected sciatic nerves from 5-d-old mice were 
processed for electron microscopy, as described previously (  Sharghi-
Namini et al., 2006  ), and viewed in an electron microscope (1010; JEOL) 
operating at 80 KV. Photographic images of 10  –  15 representative areas 
of the whole sciatic nerve were acquired at a magniﬁ  cation of 5,000 using 
a camera (Orius SC10001; Gatan) and digital micrograph software (ver-
sion 3.11.2; Gatan). Images were imported into Photoshop (version 7.0), 
and the total number of rounded or collapsed myelin sheaths per image 
was counted. Image J was used to calculate the total nerve area and the 
area represented by the images. Counts were expressed as the number of 
myelin sheaths per 10,000   μ  m 
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